| mRNA |
tacrolimus |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
1e-09 |
| mRNA |
RAF265 |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
8e-08 |
| mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
4e-05 |
| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0002 |
| mRNA |
Bexarotene |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0002 |
| mRNA |
BRD1835 |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.0002 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0003 |
| mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0003 |
| mRNA |
paclitaxel |
gCSI |
pan-cancer |
AAC |
-0.21 |
0.0004 |
| mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0005 |